199 related articles for article (PubMed ID: 21543468)
21. Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells.
Lerner DL; Elder JH
J Virol; 2000 Feb; 74(4):1854-63. PubMed ID: 10644358
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion.
Garg H; Fuller FJ; Tompkins WA
Virology; 2004 Apr; 321(2):274-86. PubMed ID: 15051387
[TBL] [Abstract][Full Text] [Related]
23. Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus.
de Parseval A; Chatterji U; Morris G; Sun P; Olson AJ; Elder JH
Nat Struct Mol Biol; 2005 Jan; 12(1):60-6. PubMed ID: 15592478
[TBL] [Abstract][Full Text] [Related]
24. Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.
Gu Q; Zhang Z; Cano Ortiz L; Franco AC; Häussinger D; Münk C
J Virol; 2016 Dec; 90(23):10545-10557. PubMed ID: 27630243
[TBL] [Abstract][Full Text] [Related]
25. Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals.
Desmaris F; Lemaire D; Ricard-Blum S; Chatrenet B; Forest E
Biochem J; 2005 Jul; 389(Pt 2):559-67. PubMed ID: 15799719
[TBL] [Abstract][Full Text] [Related]
26. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
27. Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.
Lombardi S; Garzelli C; La Rosa C; Zaccaro L; Specter S; Malvaldi G; Tozzini F; Esposito F; Bendinelli M
J Virol; 1993 Aug; 67(8):4742-9. PubMed ID: 8392611
[TBL] [Abstract][Full Text] [Related]
28. Feline immunodeficiency virus envelope glycoprotein mediates apoptosis in activated PBMC by a mechanism dependent on gp41 function.
Garg H; Joshi A; Tompkins WA
Virology; 2004 Dec; 330(2):424-36. PubMed ID: 15567436
[TBL] [Abstract][Full Text] [Related]
29. Antiviral activity of membrane fusion inhibitors that target gp40 of the feline immunodeficiency virus envelope protein.
Mizukoshi F; Baba K; Goto Y; Setoguchi A; Fujino Y; Ohno K; Oishi S; Kodera Y; Fujii N; Tsujimoto H
Vet Microbiol; 2009 Apr; 136(1-2):155-9. PubMed ID: 19036536
[TBL] [Abstract][Full Text] [Related]
30. Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope.
Richardson J; Fossati I; Moraillon A; Castelot S; Sonigo P; Pancino G
J Gen Virol; 1996 Apr; 77 ( Pt 4)():759-71. PubMed ID: 8627265
[TBL] [Abstract][Full Text] [Related]
31. Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.
Hosie MJ; Willett BJ; Klein D; Dunsford TH; Cannon C; Shimojima M; Neil JC; Jarrett O
J Virol; 2002 Jun; 76(12):6062-72. PubMed ID: 12021339
[TBL] [Abstract][Full Text] [Related]
32. Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties.
Pancino G; Castelot S; Sonigo P
Virology; 1995 Feb; 206(2):796-806. PubMed ID: 7856093
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus.
Oishi S; Kodera Y; Nishikawa H; Kamitani H; Watabe T; Ohno H; Tochikura T; Shimane K; Kodama E; Matsuoka M; Mizukoshi F; Tsujimoto H; Fujii N
Bioorg Med Chem; 2009 Jul; 17(14):4916-20. PubMed ID: 19541488
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of feline immunodeficiency virus budding.
Luttge BG; Shehu-Xhilaga M; Demirov DG; Adamson CS; Soheilian F; Nagashima K; Stephen AG; Fisher RJ; Freed EO
J Virol; 2008 Mar; 82(5):2106-19. PubMed ID: 18094166
[TBL] [Abstract][Full Text] [Related]
35. The antiviral activity of a synthetic peptide derived from the envelope SU glycoprotein of feline immunodeficiency virus maps in correspondence of an amphipathic helical segment.
Massi C; Indino E; Lami C; Fissi A; Pieroni O; La Rosa C; Esposito F; Galoppini C; Rovero P; Bandecchi P; Bendinelli M; Garzelli C
Biochem Biophys Res Commun; 1998 May; 246(1):160-5. PubMed ID: 9600086
[TBL] [Abstract][Full Text] [Related]
36. Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns.
Sodora DL; Shpaer EG; Kitchell BE; Dow SW; Hoover EA; Mullins JI
J Virol; 1994 Apr; 68(4):2230-8. PubMed ID: 8139008
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of antiviral activity of peptides from MPER of FIV gp36.
Grimaldi M; Stillitano I; Amodio G; Santoro A; Buonocore M; Moltedo O; Remondelli P; D'Ursi AM
PLoS One; 2018; 13(9):e0204042. PubMed ID: 30240422
[TBL] [Abstract][Full Text] [Related]
38. Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein.
Celestino M; Calistri A; Del Vecchio C; Salata C; Chiuppesi F; Pistello M; Borsetti A; Palù G; Parolin C
J Virol; 2012 Jun; 86(12):6688-700. PubMed ID: 22514338
[TBL] [Abstract][Full Text] [Related]
39. Characterization of pseudorabies virus glycoprotein C attachment to heparan sulfate proteoglycans.
Rue CA; Ryan P
J Gen Virol; 2002 Feb; 83(Pt 2):301-309. PubMed ID: 11807222
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
